258 related articles for article (PubMed ID: 33747510)
1. Ligelizumab treatment for severe asthma: learnings from the clinical development programme.
Trischler J; Bottoli I; Janocha R; Heusser C; Jaumont X; Lowe P; Gautier A; Pethe A; Woessner R; Zerwes HG; Zielen S
Clin Transl Immunology; 2021; 10(3):e1255. PubMed ID: 33747510
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of multiple doses of QGE031 (ligelizumab) versus omalizumab and placebo in inhibiting allergen-induced early asthmatic responses.
Gauvreau GM; Arm JP; Boulet LP; Leigh R; Cockcroft DW; Davis BE; Mayers I; FitzGerald JM; Dahlen B; Killian KJ; Laviolette M; Carlsten C; Lazarinis N; Watson RM; Milot J; Swystun V; Bowen M; Hui L; Lantz AS; Meiser K; Maahs S; Lowe PJ; Skerjanec A; Drollmann A; O'Byrne PM
J Allergy Clin Immunol; 2016 Oct; 138(4):1051-1059. PubMed ID: 27185571
[TBL] [Abstract][Full Text] [Related]
3. The mechanistic and functional profile of the therapeutic anti-IgE antibody ligelizumab differs from omalizumab.
Gasser P; Tarchevskaya SS; Guntern P; Brigger D; Ruppli R; Zbären N; Kleinboelting S; Heusser C; Jardetzky TS; Eggel A
Nat Commun; 2020 Jan; 11(1):165. PubMed ID: 31913280
[TBL] [Abstract][Full Text] [Related]
4. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab).
Milgrom H; Berger W; Nayak A; Gupta N; Pollard S; McAlary M; Taylor AF; Rohane P
Pediatrics; 2001 Aug; 108(2):E36. PubMed ID: 11483846
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high-affinity anti-IgE antibody, in atopic subjects.
Arm JP; Bottoli I; Skerjanec A; Floch D; Groenewegen A; Maahs S; Owen CE; Jones I; Lowe PJ
Clin Exp Allergy; 2014 Nov; 44(11):1371-85. PubMed ID: 25200415
[TBL] [Abstract][Full Text] [Related]
6. IgE-neutralizing UB-221 mAb, distinct from omalizumab and ligelizumab, exhibits CD23-mediated IgE downregulation and relieves urticaria symptoms.
Kuo BS; Li CH; Chen JB; Shiung YY; Chu CY; Lee CH; Liu YJ; Kuo JH; Hsu C; Su HW; Li YF; Lai A; Ho YF; Cheng YN; Huang HX; Lung MC; Wu MS; Yang FH; Lin CH; Tseng W; Yang J; Lin CY; Tsai PH; Chang HK; Wang YJ; Chen T; Lynn S; Liao MJ; Wang CY
J Clin Invest; 2022 Aug; 132(15):. PubMed ID: 35912861
[TBL] [Abstract][Full Text] [Related]
7. Ligelizumab impairs IgE-binding to plasmacytoid dendritic cells more potently than omalizumab and restores IFN-α production and FOXP3
Benito-Villalvilla C; de la Rocha-Muñoz A; López-Abente J; Eggel A; Bottoli I; Severin T; Woisetschläger M; Palomares O
Allergy; 2023 Apr; 78(4):1060-1072. PubMed ID: 36315052
[TBL] [Abstract][Full Text] [Related]
8. Ligelizumab for Chronic Spontaneous Urticaria.
Maurer M; Giménez-Arnau AM; Sussman G; Metz M; Baker DR; Bauer A; Bernstein JA; Brehler R; Chu CY; Chung WH; Danilycheva I; Grattan C; Hébert J; Katelaris C; Makris M; Meshkova R; Savic S; Sinclair R; Sitz K; Staubach P; Wedi B; Löffler J; Barve A; Kobayashi K; Hua E; Severin T; Janocha R
N Engl J Med; 2019 Oct; 381(14):1321-1332. PubMed ID: 31577874
[TBL] [Abstract][Full Text] [Related]
9. The rationale for development of ligelizumab in food allergy.
Wood RA; Chinthrajah RS; Eggel A; Bottoli I; Gautier A; Woisetschlaeger M; Tassinari P; Altman P
World Allergy Organ J; 2022 Sep; 15(9):100690. PubMed ID: 36185545
[TBL] [Abstract][Full Text] [Related]
10. Omalizumab for asthma in adults and children.
Normansell R; Walker S; Milan SJ; Walters EH; Nair P
Cochrane Database Syst Rev; 2014 Jan; 2014(1):CD003559. PubMed ID: 24414989
[TBL] [Abstract][Full Text] [Related]
11. Anti-IgE for chronic asthma in adults and children.
Walker S; Monteil M; Phelan K; Lasserson TJ; Walters EH
Cochrane Database Syst Rev; 2004; (3):CD003559. PubMed ID: 15266491
[TBL] [Abstract][Full Text] [Related]
12. Role of anti-IgE monoclonal antibody (omalizumab) in the treatment of bronchial asthma and allergic respiratory diseases.
D'Amato G
Eur J Pharmacol; 2006 Mar; 533(1-3):302-7. PubMed ID: 16464445
[TBL] [Abstract][Full Text] [Related]
13. IgE Depletion with Ligelizumab Does Not Significantly Improve Clinical Symptoms in Patients with Moderate-to-Severe Atopic Dermatitis.
Bangert C; Loesche C; Skvara H; Fölster-Holst R; Lacour JP; Jones J; Burnett P; Novak N; Stingl G
J Invest Dermatol; 2023 Oct; 143(10):1896-1905.e8. PubMed ID: 37004878
[TBL] [Abstract][Full Text] [Related]
14. Anti-IgE for chronic asthma in adults and children.
Walker S; Monteil M; Phelan K; Lasserson TJ; Walters EH
Cochrane Database Syst Rev; 2006 Apr; (2):CD003559. PubMed ID: 16625585
[TBL] [Abstract][Full Text] [Related]
15. Anti-IgE for chronic asthma.
Walker S; Monteil M; Phelan K; Lasserson TJ; Walters EH
Cochrane Database Syst Rev; 2003; (3):CD003559. PubMed ID: 12917972
[TBL] [Abstract][Full Text] [Related]
16. Omalizumab in children with inadequately controlled severe allergic (IgE-mediated) asthma.
Kulus M; Hébert J; Garcia E; Fowler Taylor A; Fernandez Vidaurre C; Blogg M
Curr Med Res Opin; 2010 Jun; 26(6):1285-93. PubMed ID: 20377320
[TBL] [Abstract][Full Text] [Related]
17. Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma.
Lanier B; Bridges T; Kulus M; Taylor AF; Berhane I; Vidaurre CF
J Allergy Clin Immunol; 2009 Dec; 124(6):1210-6. PubMed ID: 19910033
[TBL] [Abstract][Full Text] [Related]
18. Sustained safety and efficacy of ligelizumab in patients with chronic spontaneous urticaria: A one-year extension study.
Maurer M; Giménez-Arnau A; Bernstein JA; Chu CY; Danilycheva I; Hide M; Makris M; Metz M; Savic S; Sitz K; Soong W; Staubach P; Sussman G; Barve A; Burciu A; Hua E; Janocha R; Severin T
Allergy; 2022 Jul; 77(7):2175-2184. PubMed ID: 34773261
[TBL] [Abstract][Full Text] [Related]
19. The effect of omalizumab treatment on the low affinity immunoglobulin E receptor (CD23/fc epsilon RII) in patients with severe allergic asthma.
Assayag M; Moshel S; Kohan M; Berkman N
Allergy Asthma Proc; 2018 Jan; 39(1):36-42. PubMed ID: 29279058
[TBL] [Abstract][Full Text] [Related]
20. Omalizumab: a review of its use in the management of allergic asthma.
Bang LM; Plosker GL
Treat Respir Med; 2004; 3(3):183-99. PubMed ID: 15219177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
